Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rIL-2 and Bevacizumab in Metastatic Clear Cell Renal Carcinoma
NCT00853021Phase 2Completed
- Start
- Dec 2005
- Primary completion
- Oct 2009
- Modality
- Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin and bevacizumab in clear cell renal cell carcinoma (ccRCC). Primary endpoint: Progression Free Survival at 2 years. Started Dec 2005; status: completed.
02
Drugs
aldesleukinbevacizumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT00853021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00853021.